MIMS Group, an Asia-Pacific provider of medicines information, clinical decision support, medical communications, and marketing services, is accelerating product innovation and international growth as it transforms its long-standing healthcare data, content, and market expertise into new technology platforms, customer applications, and services. The strategic shift, announced via Media OutReach Newswire, signals a major evolution for a company that has been a trusted source of medical information for over six decades.
Following the appointment of Sohil Goswami as Group CEO in January 2026, MIMS has reshaped its businesses and leadership structure to support its next phase of growth. The company is now ready to harness its data, technology, and healthcare relationships to create scalable products and new business models across markets. This repositioning is critical as healthcare systems worldwide demand more integrated, digital solutions to improve patient outcomes and operational efficiency.
Central to this transformation is the expansion of MIMS' Clinical Decision Support (CDS) offerings. The company recently launched MIMS Pulse, a next-generation CDS platform that combines MIMS' medicines data and clinical knowledge with modern technology, flexible deployment, and integration capabilities to support safer and more efficient clinical workflows. Alongside MIMS Pulse, MIMS is scaling eMIMS Plus, a platform that brings trusted medicines information into a modern digital experience designed to achieve quality use of medicine. Conceived and first launched in Australia, eMIMS Plus is now available in India and Malaysia, with plans to expand across Southeast Asia, introduce new clinical modules, and extend into new healthcare categories through Drugs4Dent. MIMS is also developing its global CDS offering, building on these platforms to take its clinical data and technology capabilities into new markets and customer environments.
Simultaneously, MIMS' Medical Communications business is expanding internationally, with commercial capabilities in the US and UK creating opportunities with new client segments and global life sciences organizations. The business continues to develop digital events, AI-enabled content capabilities, and new customer engagement models. MIMS is exploring more connected, intelligence-led services that help healthcare and life sciences organizations better understand their markets, engage healthcare professionals, and make more informed decisions. This work represents an important step beyond MIMS' traditional information and communications models, applying its content data and market reach to new technology-enabled services.
Goswami commented: "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms, and services. We have been reshaping the business – bringing our capabilities together, strengthening our technology, and building new ways to serve customers across markets. Our opportunity is to turn trusted medical data, deep healthcare relationships, and market knowledge into the next generation of products, platforms, and services to build a MIMS that can compete and grow globally while staying relevant to the markets we serve."
The implications of these developments are significant. For healthcare professionals, MIMS' enhanced CDS tools promise more integrated, user-friendly access to critical drug information, potentially reducing errors and improving patient care. For the life sciences industry, MIMS' expanded medical marketing services offer new avenues for engagement and market intelligence, particularly as AI and digital capabilities become central to commercial strategies. For MIMS itself, the move positions the company to compete more effectively on a global scale, leveraging its established presence in 17 markets and over two million healthcare professional subscribers. As the healthcare landscape continues to digitize, MIMS' ability to innovate and scale its platforms will be key to its long-term growth and relevance. More information is available at https://corporate.mims.com/.
